Molecular Markers for Breast Cancer: Prediction on Tumor Behavior

Hirata, Bruna Karina Banin; Oda, Julie Massayo Maeda; Guembarovski, Roberta Losi; Ariza, Carolina Batista; Oliveira, Carlos Eduardo Coral de; Watanabe, Maria Angélica Ehara

doi:10.1155/2014/513158

Cited by 138 publications

(90 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other subtypes represent less than 10% of cases diagnosed per year. Patients with invasive ductal carcinoma present higher lymphatic involvement and worse prognosis than less common types of breast carcinoma [3].…”

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Payandeh¹,

Sadeghi²,

Sadeghi³

et al. 2014

AJCP

View full text Add to dashboard Cite

To evaluate the concordance and discordance between IHC and FISH results for detection of Her2/neu protein, analyses of ER and PR, and also evaluation of the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive ductal carcinoma enrolled onto the Herceptin adjuvant. IHC analysis of ER, PR and HER2 was performed in 133 patients of breast cancer with invasive ductal carcinoma. 90(67.6%) cases were confirmed by FISH. Statistical analysis was performed with IBM SPSS version 19, Kaplan-Meier method and log-rank test. Age mean of patients was 46.39±10.81 years (range, 24-78 years). Concordance rates between IHC and FISH were 32.4% for IHC 2+ and 81.25% for IHC 3+ (P<0.001). There were 17 and 56 patients of IHC 2+ and 3+ with ER positive and also 23 and 59 patients of IHC 2+ and 3+ had PR positive.The 83 patients had age ≤50 years and 50 patients had >50 years. Of 133 the patients, 48(36.1%) patients were treated with trastuzumab and 85(63.9%) were treated without trastuzumab. The overall survival(OS) for patients treating with trastuzumab were mean of 37.8 months and the OS for patients treating without trastuzumab were mean of 20.8 months (P<0.05). The results are that trastuzumab therapy is effective and improves the survival of HER2-positive breast cancer patients and trastuzumab therapy is effective and tolerated for breast cancer with Her-2 positive. There is a statistically significant relationship between ER positive with PR positive and ER negative with PR negative that these results need to more studies with more patients in the world.

show abstract

Section: Introductionmentioning

confidence: 94%

“…[3,9] The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Since information about ER and PR is vital for patient management, quality assurance is important to ensure accurate testing.…”

Section: Introductionmentioning

confidence: 99%

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Payandeh¹,

Sadeghi²,

Sadeghi³

et al. 2014

AJCP

View full text Add to dashboard Cite

show abstract

“…These markers are thought to be helpful in the clinical management of cancer patients, assisting in diagnostic, staging, evaluation of therapeutic response, detection of recurrence and metastasis, and the development of new treatment modalities [4]. There are few breast tumor markers being used routinely in clinics, such as follow up molecular markers (CA 15-3, CA 27.29 and CEA), markers of prognostic and/or therapeutic value (hormone receptors, HER-2, Ki-67, p53 proteins), and the genes for hereditary breast cancer [5].…”

Section: Introductionmentioning

confidence: 99%

Identification of Potential Tumor Markers in Sudanese Breast Cancer Patients Using a Proteomic Approach

Elamin¹,

Franz²,

Ibrahim³

2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Breast cancer (BC) is considered as a major health problem in Sudan, being the most frequent hospital treated malignancy and the commonest cancer affecting Sudanese females (34%). Proteomics provides tools that investigate the precise molecular defect(s) in breast cancer tissue. Moreover, it plays a growingly important role in tumor markers discovery. In this study, a proteomic assay (2D-PAGE) was used to investigate the protein profiles of a panel of 12 Sudanese breast malignant tissues and 12 matched controls. Protein spots of interest were excised manually, and in-gel digested using trypsin. Proteins were identified using mass spectrometry (MALDI-TOF). Mascot program was used to search protein databases for matching peptides from known proteins. The overall profile was relatively similar, the preliminary results identified three proteins to be differentially expressed, suggesting that they may perform a role in breast neoplasia. Although the number of samples investigated in this study is comparatively small, to allow authoritative conclusions, the study provided three proteins that might be potential tumor markers in Sudanese breast cancer patients requiring further investigations and validation.

show abstract

“…The progression of breast cancer involves various stages until the invasive carcinoma occurrence and finally into metastatic disease. Given the variability in clinical progression in breast cancer, the identification of markers that could predict the tumor behavior is particularly important [3]. Among diagnostic techniques, DNA methylation based biomarker could help as an important tool for the diagnosis of many cancers, including breast cancer [4].…”

Section: Introductionmentioning

confidence: 99%

Aberrant Vimentin Methylation Is Characteristic of Breast Cancer

Dwedar¹,

Khalil²,

Nayer³

et al. 2016

ABCR

View full text Add to dashboard Cite

Background: Epigenetic mechanisms including DNA methylation are key regulators of gene activity and may play key roles in carcinogenesis through cumulative activation and inactivation of oncogenes, tumor suppressor genes, and other genes. Increased vimentin gene expression has been reported in various tumor cell lines and tissues including breast cancer. In addition, methylation of the vimentin gene was described as a marker in several malignant tumors. Objective: The aim of this study is to determine the existence of a potential relationship between the methylation state of the vimentin gene and its prognostic value in breast cancer patients and its correlation with vimentin protein expression in the serum. Patients and Methods: The methylation status of the vimentin gene was examined in primary infiltrating ductaltumors and the surrounding normal tissues derived from 50 breast cancer patients enrolled for either modified radical mastectomy or conservative breast surgery using quantitative methylation-specific polymerase chain reaction (qMSP), serum vimentin levels were determined using ELISA, and the correlation between the methylation status and the clinicopathological findings was evaluated. Results: Out of 50 breast cancer patients, 18 (36%) exhibited positive methylation of vimentin gene while 32 (64%) exhibited negative vimentin genemethylation in their tumors. Subsequently clinicopathological data were correlated with the vimentin genemethylation score. A significant association was found between negative vimentin methylation, and both serum vimentin protein level (p < 0.001) and the triple negative breast cancer subtype (TNBCs) (p = 0.004). Using receiver-operating characteristic (ROC) curve analysis, a cut off value of <0.49 was set for the negative vimentin methylation score to distinguish between early and late stage breast cancer, and the ROC curve showed an area under the curve (AUC) of 0.684 (p = 0.029). Conclusion: Our study showed that the vimentin gene is frequently hypomethylated in breast cancer tissues, and that 151negative methylation status is always associated with high serum vimentin protein expression levels. Also we reported a significant association between negative vimentin methylation and TNBC subtype which is known to have an aggressive clinical course. Taken together, these results might have important implications for the design of novel therapeutic interventions for breast cancer patients. However, further studies with larger sample size are needed to validate these observations.

show abstract

Molecular Markers for Breast Cancer: Prediction on Tumor Behavior

Cited by 138 publications

References 133 publications

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Identification of Potential Tumor Markers in Sudanese Breast Cancer Patients Using a Proteomic Approach

Aberrant Vimentin Methylation Is Characteristic of Breast Cancer

Contact Info

Product

Resources

About